The President is the master of the art of the deal. And now he’s using his skills for everyone.
Because Trump struck an historic deal that could save average Americans thousands of dollars.
Trump Secures Drug Price Cuts from AstraZeneca
The Trump administration finalized an agreement with AstraZeneca on Friday to slash prescription drug costs, the second major pharmaceutical firm in two weeks to comply with President Trump’s push for affordable medicines.
The pact follows a similar arrangement with Pfizer just 10 days earlier, where Trump compelled companies to implement “Most Favored Nation” pricing, aligning U.S. rates with cheaper international benchmarks.
“It’s pretty beautiful to watch AstraZeneca, the largest pharmaceutical manufacturer in the United Kingdom, committing to offer Americans major discounts on their vast catalog of prescription drugs,” Mr. Trump said from the Oval Office.
Select AstraZeneca medications will become available at reduced rates on the forthcoming TrumpRx platform, set to launch next year.
Major U.S. Investment and Job Growth
Mr. Trump further revealed that the U.K.-headquartered AstraZeneca pledged $50 billion for U.S. investments over five years, focusing on research, development, and production sites. The company initiated construction on a new facility in Charlottesville, Virginia, on Thursday, projected to generate 3,600 jobs, according to the president.
AstraZeneca CEO Pascal Soriot described the agreement as “a big win for the economy and for taxpayers.”
U.S. consumers currently face brand-name drug prices over three times those in other high-income nations within the Organization for Economic Cooperation and Development, even factoring in domestic manufacturer rebates, based on federal figures.
The U.S. accounts for under 5% of global population yet drives roughly 75% of worldwide pharmaceutical earnings from American buyers.
Trump’s Offensive Against High Drug Costs
Successive presidents across parties have targeted the steep prescription burdens on Americans.
Drug firms leverage substantial U.S. research incentives and healthcare outlays, yet pass little savings to domestic purchasers.
Companies instead offer foreign discounts to penetrate overseas markets, offsetting those reductions via elevated U.S. charges, effectively making Americans foot the bill for both corporate gains and international health programs in R&D and sales.
In May, Mr. Trump issued an executive order mandating steps to equalize U.S. drug pricing with peer countries.
Late July letters to leading manufacturers outlined required measures to match the lowest rates in developed nations.
“In case after case, our citizens pay massively higher prices than other nations pay for the same pill, from the same factory, effectively subsidizing socialism abroad with skyrocketing prices at home,” Mr. Trump stated then.
“So, we would spend tremendous amounts of money in order to provide inexpensive drugs to another country. And when I say the price is different, you can see some examples where the price is beyond anything — four times, five times different.”
